Release Date
June 7, 2011
|
Expiration Date
June 7, 2012 |
|
| Faculty |
Melanoma:
Antoni Ribas, MD
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
|
Ovarian Cancer:
Amit Oza, MD
Princess Margaret Hospital
Toronto, Ontario, Canada
|
Genitourinary Malignancies:
Dean Bajorin, MD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
Vernon Sondak, MD
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
|
Bradley Monk, MD
Creighton University School of Medicine
at St Joseph's Hospital and Medical Center
Phoenix, Arizona, United States
|
|
Target Audience
This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, pathologists, radiologists, and other healthcare providers involved and/or interested in the care of patients with cancer. |
Overview
These interviews discuss recently released data from the 2011 Oncology Annual Meeting in Chicago, focusing on various aspects of the management of patients with cancer. |
Educational Objectives
Upon completion of this educational activity, participants should be able to:
- Evaluate emerging clinical trial data pertaining to melanoma presented at the 2011 Oncology Annual Meeting and how these data should be incorporated into current standards of care to improve patient outcomes
- Discuss the utility of novel agents or combinatorial strategies that may provide superior disease outcomes for patients with gynecologic malignancies compared to outcomes obtained with current standards of care
- Integrate multimodality treatment strategies, including radiation therapy, chemotherapy, and targeted therapy, into the management of patients with genitourinary malignancies
|
Sponsorship
This activity is sponsored by prIME Oncology. |
Continuing Medical Education
prIME Oncology is accredited by the Accreditation Council of Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. |
Credit Designation Statement
prIME Oncology designates this enduring Internet-based educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Each interview may provide the following credits:
2011555: Daily Clinical Updates from the 2011 Oncology Annual Meeting in Chicago – Melanoma – 0.25 CME credits
2011556: Daily Clinical Updates from the 2011 Oncology Annual Meeting in Chicago – Ovarian Cancer – 0.50 CME credits
2011578: Daily Clinical Updates from the 2011 Oncology Annual Meeting in Chicago – Genitourinary Malignancies – 0.50 CME credits
|
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you.
Links to the post tests are available on the video player pages. |
Support Statements
The Melanoma Daily Clinical Update activity is supported by educational grants from Genentech BioOncology and Merck Oncology.
The Ovarian Cancer Daily Clinical Update activity is supported by educational grants from Genentech BioOncology and Pharma Mar s.a.u. Grupo Zelta.
The Genitourinary Malignancies Daily Clinical Update activity is supported by an educational grant from Endo Pharmaceuticals. |
Disclosure of Conflicts of Interest
prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME Activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty and planners, along with their spouses/life partners, have reported the following relevant financial relationships (or absence thereof) with the commercial supporters of this activity.
Melanoma:
Dr Ribas has disclosed that he has received consulting fees from BMS; Roche; Genentech; Amgen; and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Sondak has disclosed that he is a member of the advisory board or has received consulting fees from Merck (Schering); Pfizer; BMS/Medarex; GlaxoSmithKline; Abbott; Eli Lilly; Biovex; and Provectus. He has received other fees (non-CME services) from Merck (Schering). He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Ovarian Cancer:
Dr Monk has disclosed that he has received consulting fees from VentiRx; Qiagen; Roche; GlaxoSmithKline; and Merck. He has received other fees (non-CME services) from GlaxoSmithKline; Eli Lilly; Roche; and Johnson & Johnson. He has also performed contracted research for GlaxoSmithKline; PharmaMar; sanofi-aventis; Merck; and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Oza has declared that he has no relevant financial relationships to the commercial supporters of this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Genitourinary Malignancies:
Dr Bajorin has disclosed that he has received consulting fees from Bristol Myers, and Novartis. He has received other fees (non-CME) from Eli Lilly. He also performed contracted research for Genentech, Novartis, Eli Lilly, Dendreon, and Amgen.
The employees of prIME Oncology have disclosed:
- Janice Galleshaw, MD (medical director) – no relevant financial relationships to disclose
- Amy Furedy, RN (clinical) – no relevant financial relationships to disclose
- Trudy Stoddert, ELS (editorial) – no relevant financial relationships to disclose
- Susan H Yarbrough, CCMEP (compliance) – no relevant financial relationships to disclose
|
Disclosure of Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings. |
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
|
